Milan-based NanoPhoria Bioscience at this time introduced the profitable first shut of its €83.5 million Collection A financing spherical – the biggest ever Collection A spherical in Italian BioTech historical past – for its lung-to-heart drug supply platform.
The spherical was led by XGEN Enterprise, Sofinnova Companions, and CDP Enterprise Capital, with Panakes Companions additionally investing and one different undisclosed investor becoming a member of the spherical.
“This financing is a transformational milestone for NanoPhoria,” stated Claudio De Luca, CEO and Co-founder. “It permits us to speed up medical growth of NP-MP1 and increase our pipeline. Our modern supply platform permits us to focus on beforehand inaccessible mobile targets within the cardiomyocyte, thereby bringing us nearer to delivering life-changing therapies for sufferers dwelling with severe cardiac and different power situations who’re underserved by current therapies.”
“We’re profoundly grateful to our scientific founders, our traders, our Board, and our Chair, Suman Shirodkar, whose imaginative and prescient and efforts have formed NanoPhoria’s progress and ambition,” he added.
NanoPhoria’s Collection A represents one of many largest European BioTech financings of 2025 within the cardiovascular subject. Whereas a number of there have been a number of notable investments for cardiac diagnostics and therapeutic innovation, few have matched this scale at such an early stage.
For instance, Ultromics within the UK secured €48 million to increase its AI-based cardiology diagnostics; DESKi in France raised €5.2 million for its cardiac imaging platform; and Maxion Therapeutics attracted €68 million to advance its “knotbody” drug platform.
Different BioTech rounds, resembling Ciloa’s €6.5 million to develop exosome therapies and SeaBeLife’s €2 million to pursue dual-pathway inhibitors, replicate continued investor curiosity in life sciences innovation.
Nevertheless, NanoPhoria stands out as each Italy-based and centered on cardiovascular drug growth – an space with comparatively few high-value rounds this yr – signalling sturdy investor confidence in focused supply applied sciences and next-generation therapies for coronary heart illness.
“NanoPhoria’s platform has the potential to redefine remedy paradigms in cardiovascular and different power ailments which is why we’re excited to speculate on this firm,” added Henrijette Richter, Managing Companion at Sofinnova Companions. “This financing builds on the early help of my colleague Lucia Faccio, Companion within the Sofinnova Telethon Technique, whose function was instrumental in supporting the corporate in its early days to take form. The funding displays Sofinnova’s broader dedication to backing world-class science throughout Europe, from early-stage firm creation to late-stage progress.”
Based in 2022, NanoPhoria is a preclinical-stage BioTech firm pioneering inhalable cardiovascular therapies by means of non-viral nano-delivery of biologics. The corporate is creating an modern proprietary platform designed for tissue-directed supply of therapeutic peptides and RNAs. On the core of this expertise is an inorganic calcium-phosphate nanoparticle – a flexible, biomimetic nano-carrier that may be loaded or surface-decorated with biologics and formulated for inhalation or different routes of administration.
The funding will propel NanoPhoria’s lead candidate, NP-MP1, by means of IND-enabling research and early medical growth. NP-MP1 is a first-in-class peptide that targets cardiac L-type calcium channels to enhance ejection fraction for the remedy of coronary heart failure with lowered ejection fraction (HFrEF).
Delivered by way of NanoPhoria’s proprietary lung-to-heart nano-in-micro expertise, NP-MP1 has reportedly demonstrated glorious efficacy in preclinical mannequins of coronary heart failure and goals to handle a root reason for HFrEF by enhancing cardiac contractility.
HFrEF is a situation affecting hundreds of thousands globally with a five-year mortality charge of roughly 40%.
“This funding completely aligns with XGEN’s technique to steer early financing rounds in probably the most modern Italian startups that handle true medical wants,” stated Paolo Fundarò, Managing Companion at XGEN Enterprise. “NanoPhoria’s science supplies a novel, and viable, manner of delivering extremely potent therapeutics on to the center and we sit up for working alongside such a implausible syndicate of traders.”
